Urinary Stones with MCC DRG: Reimbursement & Medicare

DRG 693 addresses inpatient admissions for urinary stones complicated by a Major Complication or Comorbidity, such as severe infection or acute renal failure, that increases resource needs. This grouping matters for inpatient reimbursement because it assigns higher payment weights to reflect greater intensity of care, longer stays, and increased costs under Medicare payment rules.

DRG 693 Overview

DRG 693 covers inpatient admissions for urinary stones with a Major Complication or Comorbidity where the presence of a significant secondary condition increases resource use. Typical clinical scenarios include obstructing renal or ureteral calculi with severe infection, sepsis, acute renal failure, or other major comorbid conditions requiring intensified inpatient management. This Diagnosis-Related Group influences Medicare payment by assigning higher relative weight and reimbursement to reflect increased intensity of care, extended length of stay, and greater resource consumption. Understanding this classification is important for accurate case grouping and hospital revenue integrity under Medicare inpatient prospective payment.

Acute procedural and perioperative trials evaluating optimized surgical or endourological techniques (eg, comparisons of lithotripsy energy settings, ureteroscopy approaches, or timing of stent placement) in hospitalized patients with urinary stones complicated by major comorbidities. These studies enroll patients admitted for obstructing stones with systemic complications (eg, sepsis, acute kidney injury, or severe cardiac/pulmonary disease) to assess procedural success, complication rates, and short-term recovery metrics. Results inform clinicians about safest, most effective acute interventions for high-risk inpatients and help payers understand resource use, length of stay, and complication-driven costs tied to specific procedural strategies.
Comparative effectiveness and risk-stratification studies that examine conservative versus interventional management in medically complex patients with urinary stones, often using registry or observational cohorts. These trials focus on older adults or patients with significant MCC (eg, CKD, heart failure, or coagulopathy) to determine which patients benefit from immediate invasive management versus delayed or medical therapies, and to identify predictors of readmission and deteriorating renal function. Findings are relevant to providers making individualized care decisions and to payers designing guidelines and bundled payment models that balance clinical benefit with avoidance of preventable complications and readmissions.
Post-discharge outcomes and care coordination research assessing transitional care, secondary prevention, and long-term renal outcomes in survivors of complicated stone admissions. Studies follow discharged patients with prior obstructing stones and MCC to evaluate adherence to metabolic evaluation, recurrence rates, chronic kidney disease progression, and the impact of outpatient care pathways (eg, care navigation, nephrology follow-up) on readmissions and downstream costs. This research helps health systems and payers target interventions that reduce recurrent hospitalizations and long-term morbidity in a high-cost DRG population.

Acute procedural and perioperative trials evaluating optimized surgical or endourological techniques (eg, comparisons of lithotripsy energy settings, ureteroscopy approaches, or timing of stent placement) in hospitalized patients with urinary stones complicated by major comorbidities. These studies enroll patients admitted for obstructing stones with systemic complications (eg, sepsis, acute kidney injury, or severe cardiac/pulmonary disease) to assess procedural success, complication rates, and short-term recovery metrics. Results inform clinicians about safest, most effective acute interventions for high-risk inpatients and help payers understand resource use, length of stay, and complication-driven costs tied to specific procedural strategies.
Comparative effectiveness and risk-stratification studies that examine conservative versus interventional management in medically complex patients with urinary stones, often using registry or observational cohorts. These trials focus on older adults or patients with significant MCC (eg, CKD, heart failure, or coagulopathy) to determine which patients benefit from immediate invasive management versus delayed or medical therapies, and to identify predictors of readmission and deteriorating renal function. Findings are relevant to providers making individualized care decisions and to payers designing guidelines and bundled payment models that balance clinical benefit with avoidance of preventable complications and readmissions.
Post-discharge outcomes and care coordination research assessing transitional care, secondary prevention, and long-term renal outcomes in survivors of complicated stone admissions. Studies follow discharged patients with prior obstructing stones and MCC to evaluate adherence to metabolic evaluation, recurrence rates, chronic kidney disease progression, and the impact of outpatient care pathways (eg, care navigation, nephrology follow-up) on readmissions and downstream costs. This research helps health systems and payers target interventions that reduce recurrent hospitalizations and long-term morbidity in a high-cost DRG population.

OpenPayer

Summary & Overview

Urinary Stones with MCC: Inpatient Reimbursement Overview

DRG 693 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes